Cancer cells consume oxygen and nutrients at a higher rate than healthy tissue,. This drug delivery system senses those physical changes and guides medicine to the disease. The drug is released only when it encounters those tumor-specific conditions.
A new study led by researchers from VIB and KU Leuven shows that immune cells called microglia can actively promote the formation of plaques in Alzheimer’s disease.
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.
Researchers from the University of California San Diego have found that a novel blood-based biomarker can predict a woman’s risk of developing dementia as many as 25 years before symptoms appear.
A research team led by Professor Jaehyuk Cho from the Department of Software Engineering at Jeonbuk National University in South Korea, have developed an innovative model, named BiT-MAML, aimed at tackling inter-patient variability in BG prediction.
Cedars-Sinai investigators working to optimize a cell-based treatment for retinitis pigmentosa have uncovered how transplanted neural stem cells interact with host retinal cells to preserve vision.
Researchers at Boston University Chobanian & Avedisian School of Medicine now show that it is possible to remove the caudate lobe safely using a surgical robot, even in an older patient, and still remove the cancer completely.
A machine-learning model developed by Weill Cornell Medicine investigators may provide clinicians with an early warning of a complication that can occur late in pregnancy.
Researchers have found that targeted delivery of messenger RNA (mRNA) can restore sperm production and fertility in genetically infertile male mice.
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don’t respond to immunotherapy.